

AMENDMENTS TO LB236
(Amendments to AM1388)

Introduced by Hansen, B., 16.

1 1. Insert the following new sections:

2 Section 1. Section 28-401, Revised Statutes Cumulative Supplement,
3 2020, is amended to read:

4 28-401 As used in the Uniform Controlled Substances Act, unless the
5 context otherwise requires:

6 (1) Administer means to directly apply a controlled substance by
7 injection, inhalation, ingestion, or any other means to the body of a
8 patient or research subject;

9 (2) Agent means an authorized person who acts on behalf of or at the
10 direction of another person but does not include a common or contract
11 carrier, public warehouse keeper, or employee of a carrier or warehouse
12 keeper;

13 (3) Administration means the Drug Enforcement Administration of the
14 United States Department of Justice;

15 (4) Controlled substance means a drug, biological, substance, or
16 immediate precursor in Schedules I through V of section 28-405.
17 Controlled substance does not include distilled spirits, wine, malt
18 beverages, tobacco, hemp, or any nonnarcotic substance if such substance
19 may, under the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. 301 et
20 seq., as such act existed on January 1, 2014, and the law of this state,
21 be lawfully sold over the counter without a prescription;

22 (5) Counterfeit substance means a controlled substance which, or the
23 container or labeling of which, without authorization, bears the
24 trademark, trade name, or other identifying mark, imprint, number, or
25 device, or any likeness thereof, of a manufacturer, distributor, or
26 dispenser other than the person or persons who in fact manufactured,

1 distributed, or dispensed such substance and which thereby falsely
2 purports or is represented to be the product of, or to have been
3 distributed by, such other manufacturer, distributor, or dispenser;

4 (6) Department means the Department of Health and Human Services;

5 (7) Division of Drug Control means the personnel of the Nebraska
6 State Patrol who are assigned to enforce the Uniform Controlled
7 Substances Act;

8 (8) Dispense means to deliver a controlled substance to an ultimate
9 user or a research subject pursuant to a medical order issued by a
10 practitioner authorized to prescribe, including the packaging, labeling,
11 or compounding necessary to prepare the controlled substance for such
12 delivery;

13 (9) Distribute means to deliver other than by administering or
14 dispensing a controlled substance;

15 (10) Prescribe means to issue a medical order;

16 (11) Drug means (a) articles recognized in the official United
17 States Pharmacopoeia, official Homeopathic Pharmacopoeia of the United
18 States, official National Formulary, or any supplement to any of them,
19 (b) substances intended for use in the diagnosis, cure, mitigation,
20 treatment, or prevention of disease in human beings or animals, and (c)
21 substances intended for use as a component of any article specified in
22 subdivision (a) or (b) of this subdivision, but does not include devices
23 or their components, parts, or accessories;

24 (12) Deliver or delivery means the actual, constructive, or
25 attempted transfer from one person to another of a controlled substance,
26 whether or not there is an agency relationship;

27 (13) Hemp has the same meaning as in section 2-503;

28 (14)(a) Marijuana means all parts of the plant of the genus
29 cannabis, whether growing or not, the seeds thereof, and every compound,
30 manufacture, salt, derivative, mixture, or preparation of such plant or
31 its seeds.

1 (b) Marijuana does not include the mature stalks of such plant,
2 hashish, tetrahydrocannabinols extracted or isolated from the plant,
3 fiber produced from such stalks, oil or cake made from the seeds of such
4 plant, any other compound, manufacture, salt, derivative, mixture, or
5 preparation of such mature stalks, the sterilized seed of such plant
6 which is incapable of germination, or cannabidiol contained in a drug
7 product approved by the federal Food and Drug Administration—~~or obtained~~
8 ~~pursuant to sections 28-463 to 28-468.~~

9 (c) Marijuana does not include hemp.

10 (d) When the weight of marijuana is referred to in the Uniform
11 Controlled Substances Act, it means its weight at or about the time it is
12 seized or otherwise comes into the possession of law enforcement
13 authorities, whether cured or uncured at that time.

14 (e) When industrial hemp as defined in section 2-5701 is in the
15 possession of a person as authorized under section 2-5701, it is not
16 considered marijuana for purposes of the Uniform Controlled Substances
17 Act;

18 (15) Manufacture means the production, preparation, propagation,
19 conversion, or processing of a controlled substance, either directly or
20 indirectly, by extraction from substances of natural origin,
21 independently by means of chemical synthesis, or by a combination of
22 extraction and chemical synthesis, and includes any packaging or
23 repackaging of the substance or labeling or relabeling of its container.
24 Manufacture does not include the preparation or compounding of a
25 controlled substance by an individual for his or her own use, except for
26 the preparation or compounding of components or ingredients used for or
27 intended to be used for the manufacture of methamphetamine, or the
28 preparation, compounding, conversion, packaging, or labeling of a
29 controlled substance: (a) By a practitioner as an incident to his or her
30 prescribing, administering, or dispensing of a controlled substance in
31 the course of his or her professional practice; or (b) by a practitioner,

1 or by his or her authorized agent under his or her supervision, for the
2 purpose of, or as an incident to, research, teaching, or chemical
3 analysis and not for sale;

4 (16) Narcotic drug means any of the following, whether produced
5 directly or indirectly by extraction from substances of vegetable origin,
6 independently by means of chemical synthesis, or by a combination of
7 extraction and chemical synthesis: (a) Opium, opium poppy and poppy
8 straw, coca leaves, and opiates; (b) a compound, manufacture, salt,
9 derivative, or preparation of opium, coca leaves, or opiates; or (c) a
10 substance and any compound, manufacture, salt, derivative, or preparation
11 thereof which is chemically equivalent to or identical with any of the
12 substances referred to in subdivisions (a) and (b) of this subdivision,
13 except that the words narcotic drug as used in the Uniform Controlled
14 Substances Act does not include decocainized coca leaves or extracts of
15 coca leaves, which extracts do not contain cocaine or ecgonine, or
16 isoquinoline alkaloids of opium;

17 (17) Opiate means any substance having an addiction-forming or
18 addiction-sustaining liability similar to morphine or being capable of
19 conversion into a drug having such addiction-forming or addiction-
20 sustaining liability. Opiate does not include the dextrorotatory isomer
21 of 3-methoxy-n methylmorphinan and its salts. Opiate includes its racemic
22 and levorotatory forms;

23 (18) Opium poppy means the plant of the species *Papaver somniferum*
24 L., except the seeds thereof;

25 (19) Poppy straw means all parts, except the seeds, of the opium
26 poppy after mowing;

27 (20) Person means any corporation, association, partnership, limited
28 liability company, or one or more persons;

29 (21) Practitioner means a physician, a physician assistant, a
30 dentist, a veterinarian, a pharmacist, a podiatrist, an optometrist, a
31 certified nurse midwife, a certified registered nurse anesthetist, a

1 nurse practitioner, a scientific investigator, a pharmacy, a hospital, or
2 any other person licensed, registered, or otherwise permitted to
3 distribute, dispense, prescribe, conduct research with respect to, or
4 administer a controlled substance in the course of practice or research
5 in this state, including an emergency medical service as defined in
6 section 38-1207;

7 (22) Production includes the manufacture, planting, cultivation, or
8 harvesting of a controlled substance;

9 (23) Immediate precursor means a substance which is the principal
10 compound commonly used or produced primarily for use and which is an
11 immediate chemical intermediary used or likely to be used in the
12 manufacture of a controlled substance, the control of which is necessary
13 to prevent, curtail, or limit such manufacture;

14 (24) State means the State of Nebraska;

15 (25) Ultimate user means a person who lawfully possesses a
16 controlled substance for his or her own use, for the use of a member of
17 his or her household, or for administration to an animal owned by him or
18 her or by a member of his or her household;

19 (26) Hospital has the same meaning as in section 71-419;

20 (27) Cooperating individual means any person, other than a
21 commissioned law enforcement officer, who acts on behalf of, at the
22 request of, or as agent for a law enforcement agency for the purpose of
23 gathering or obtaining evidence of offenses punishable under the Uniform
24 Controlled Substances Act;

25 (28)(a) Hashish or concentrated cannabis means (i) the separated
26 resin, whether crude or purified, obtained from a plant of the genus
27 cannabis or (ii) any material, preparation, mixture, compound, or other
28 substance which contains ten percent or more by weight of
29 tetrahydrocannabinols.

30 (b) When resins extracted from (i) industrial hemp as defined in
31 section 2-5701 are in the possession of a person as authorized under

1 section 2-5701 or (ii) hemp as defined in section 2-503 are in the
2 possession of a person as authorized under the Nebraska Hemp Farming Act,
3 they are not considered hashish or concentrated cannabis for purposes of
4 the Uniform Controlled Substances Act. ÷

5 (c) Hashish or concentrated cannabis does not include cannabidiol
6 contained in a drug product approved by the federal Food and Drug
7 Administration;

8 (29) Exceptionally hazardous drug means (a) a narcotic drug, (b)
9 thiophene analog of phencyclidine, (c) phencyclidine, (d) amobarbital,
10 (e) secobarbital, (f) pentobarbital, (g) amphetamine, or (h)
11 methamphetamine;

12 (30) Imitation controlled substance means a substance which is not a
13 controlled substance or controlled substance analogue but which, by way
14 of express or implied representations and consideration of other relevant
15 factors including those specified in section 28-445, would lead a
16 reasonable person to believe the substance is a controlled substance or
17 controlled substance analogue. A placebo or registered investigational
18 drug manufactured, distributed, possessed, or delivered in the ordinary
19 course of practice or research by a health care professional shall not be
20 deemed to be an imitation controlled substance;

21 (31)(a) Controlled substance analogue means a substance (i) the
22 chemical structure of which is substantially similar to the chemical
23 structure of a Schedule I or Schedule II controlled substance as provided
24 in section 28-405 or (ii) which has a stimulant, depressant, analgesic,
25 or hallucinogenic effect on the central nervous system that is
26 substantially similar to or greater than the stimulant, depressant,
27 analgesic, or hallucinogenic effect on the central nervous system of a
28 Schedule I or Schedule II controlled substance as provided in section
29 28-405. A controlled substance analogue shall, to the extent intended for
30 human consumption, be treated as a controlled substance under Schedule I
31 of section 28-405 for purposes of the Uniform Controlled Substances Act;

1 and

2 (b) Controlled substance analogue does not include (i) a controlled
3 substance, (ii) any substance generally recognized as safe and effective
4 within the meaning of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C.
5 301 et seq., as such act existed on January 1, 2014, (iii) any substance
6 for which there is an approved new drug application, or (iv) with respect
7 to a particular person, any substance if an exemption is in effect for
8 investigational use for that person, under section 505 of the Federal
9 Food, Drug, and Cosmetic Act, 21 U.S.C. 355, as such section existed on
10 January 1, 2014, to the extent conduct with respect to such substance is
11 pursuant to such exemption;

12 (32) Anabolic steroid means any drug or hormonal substance,
13 chemically and pharmacologically related to testosterone (other than
14 estrogens, progestins, and corticosteroids), that promotes muscle growth
15 and includes any controlled substance in Schedule III(d) of section
16 28-405. Anabolic steroid does not include any anabolic steroid which is
17 expressly intended for administration through implants to cattle or other
18 nonhuman species and has been approved by the Secretary of Health and
19 Human Services for such administration, but if any person prescribes,
20 dispenses, or distributes such a steroid for human use, such person shall
21 be considered to have prescribed, dispensed, or distributed an anabolic
22 steroid within the meaning of this subdivision;

23 (33) Chart order means an order for a controlled substance issued by
24 a practitioner for a patient who is in the hospital where the chart is
25 stored or for a patient receiving detoxification treatment or maintenance
26 treatment pursuant to section 28-412. Chart order does not include a
27 prescription;

28 (34) Medical order means a prescription, a chart order, or an order
29 for pharmaceutical care issued by a practitioner;

30 (35) Prescription means an order for a controlled substance issued
31 by a practitioner. Prescription does not include a chart order;

1 (36) Registrant means any person who has a controlled substances
2 registration issued by the state or the Drug Enforcement Administration
3 of the United States Department of Justice;

4 (37) Reverse distributor means a person whose primary function is to
5 act as an agent for a pharmacy, wholesaler, manufacturer, or other entity
6 by receiving, inventorying, and managing the disposition of outdated,
7 expired, or otherwise nonsaleable controlled substances;

8 (38) Signature means the name, word, or mark of a person written in
9 his or her own hand with the intent to authenticate a writing or other
10 form of communication or a digital signature which complies with section
11 86-611 or an electronic signature;

12 (39) Facsimile means a copy generated by a system that encodes a
13 document or photograph into electrical signals, transmits those signals
14 over telecommunications lines, and reconstructs the signals to create an
15 exact duplicate of the original document at the receiving end;

16 (40) Electronic signature has the definition found in section
17 86-621;

18 (41) Electronic transmission means transmission of information in
19 electronic form. Electronic transmission includes computer-to-computer
20 transmission or computer-to-facsimile transmission;

21 (42) Long-term care facility means an intermediate care facility, an
22 intermediate care facility for persons with developmental disabilities, a
23 long-term care hospital, a mental health substance use treatment center,
24 a nursing facility, or a skilled nursing facility, as such terms are
25 defined in the Health Care Facility Licensure Act;

26 (43) Compounding has the same meaning as in section 38-2811;

27 (44) Cannabinoid receptor agonist means ~~shall mean~~ any chemical
28 compound or substance that, according to scientific or medical research,
29 study, testing, or analysis, demonstrates the presence of binding
30 activity at one or more of the CB1 or CB2 cell membrane receptors located
31 within the human body. Cannabinoid receptor agonist does not include

1 cannabidiol contained in a drug product approved by the federal Food and
2 Drug Administration; and

3 (45) Lookalike substance means a product or substance, not
4 specifically designated as a controlled substance in section 28-405, that
5 is either portrayed in such a manner by a person to lead another person
6 to reasonably believe that it produces effects on the human body that
7 replicate, mimic, or are intended to simulate the effects produced by a
8 controlled substance or that possesses one or more of the following
9 indicia or characteristics:

10 (a) The packaging or labeling of the product or substance suggests
11 that the user will achieve euphoria, hallucination, mood enhancement,
12 stimulation, or another effect on the human body that replicates or
13 mimics those produced by a controlled substance;

14 (b) The name or packaging of the product or substance uses images or
15 labels suggesting that it is a controlled substance or produces effects
16 on the human body that replicate or mimic those produced by a controlled
17 substance;

18 (c) The product or substance is marketed or advertised for a
19 particular use or purpose and the cost of the product or substance is
20 disproportionately higher than other products or substances marketed or
21 advertised for the same or similar use or purpose;

22 (d) The packaging or label on the product or substance contains
23 words or markings that state or suggest that the product or substance is
24 in compliance with state and federal laws regulating controlled
25 substances;

26 (e) The owner or person in control of the product or substance uses
27 evasive tactics or actions to avoid detection or inspection of the
28 product or substance by law enforcement authorities;

29 (f) The owner or person in control of the product or substance makes
30 a verbal or written statement suggesting or implying that the product or
31 substance is a synthetic drug or that consumption of the product or

1 substance will replicate or mimic effects on the human body to those
2 effects commonly produced through use or consumption of a controlled
3 substance;

4 (g) The owner or person in control of the product or substance makes
5 a verbal or written statement to a prospective customer, buyer, or
6 recipient of the product or substance implying that the product or
7 substance may be resold for profit; or

8 (h) The product or substance contains a chemical or chemical
9 compound that does not have a legitimate relationship to the use or
10 purpose claimed by the seller, distributor, packer, or manufacturer of
11 the product or substance or indicated by the product name, appearing on
12 the product's packaging or label or depicted in advertisement of the
13 product or substance.

14 Sec. 2. Section 28-405, Revised Statutes Cumulative Supplement,
15 2020, is amended to read:

16 28-405 The following are the schedules of controlled substances
17 referred to in the Uniform Controlled Substances Act, unless specifically
18 contained on the list of exempted products of the Drug Enforcement
19 Administration of the United States Department of Justice as the list
20 existed on January 31, 2021 ~~November 9, 2017~~:

21 Schedule I

22 (a) Any of the following opiates, including their isomers, esters,
23 ethers, salts, and salts of isomers, esters, and ethers, unless
24 specifically excepted, whenever the existence of such isomers, esters,
25 ethers, and salts is possible within the specific chemical designation:

26 (1) Acetylmethadol;

27 (2) Allylprodine;

28 (3) Alphacetylmethadol, except levo-alphacetylmethadol which is also
29 known as levo-alpha-acetylmethadol, levomethadyl acetate, and LAAM;

30 (4) Alphameprodine;

31 (5) Alphamethadol;

- 1 (6) Benzethidine;
- 2 (7) Betacetylmethadol;
- 3 (8) Betameprodine;
- 4 (9) Betamethadol;
- 5 (10) Betaprodine;
- 6 (11) Clonitazene;
- 7 (12) Dextromoramide;
- 8 (13) DifenoXin;
- 9 (14) Diampromide;
- 10 (15) Diethylthiambutene;
- 11 (16) Dimenoxadol;
- 12 (17) Dimepheptanol;
- 13 (18) Dimethylthiambutene;
- 14 (19) Dioxaphetyl butyrate;
- 15 (20) Dipipanone;
- 16 (21) Ethylmethylthiambutene;
- 17 (22) Etonitazene;
- 18 (23) EtoXeridine;
- 19 (24) Furethidine;
- 20 (25) Hydroxypethidine;
- 21 (26) Ketobemidone;
- 22 (27) Levomoramide;
- 23 (28) Levophenacymorphan;
- 24 (29) Morpheridine;
- 25 (30) Noracymethadol;
- 26 (31) Norlevorphanol;
- 27 (32) Normethadone;
- 28 (33) Norpipanone;
- 29 (34) Phenadoxone;
- 30 (35) Phenampromide;
- 31 (36) Phenomorphan;

- 1 (37) Phenoperidine;
- 2 (38) Piritramide;
- 3 (39) Proheptazine;
- 4 (40) Properidine;
- 5 (41) Propiram;
- 6 (42) Racemoramide;
- 7 (43) Trimeperidine;
- 8 (44) Alpha-methylfentanyl, N-(1-(alpha-methyl-beta-phenyl)ethyl-4-
- 9 piperidyl) propionanilide, 1-(1-methyl-2-phenylethyl)-4-(N-propanilido)
- 10 piperidine;
- 11 (45) Tilidine;
- 12 (46) 3-Methylfentanyl, N-(3-methyl-1-(2-phenylethyl)-4-piperidyl)-N-
- 13 phenylpropanamide, its optical and geometric isomers, salts, and salts of
- 14 isomers;
- 15 (47) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP), its optical
- 16 isomers, salts, and salts of isomers;
- 17 (48) PEPAP, 1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine, its
- 18 optical isomers, salts, and salts of isomers;
- 19 (49) Acetyl-alpha-methylfentanyl, N-(1-(1-methyl-2-phenethyl)-4-
- 20 piperidinyl)-N-phenylacetamide, its optical isomers, salts, and salts of
- 21 isomers;
- 22 (50) Alpha-methylthiofentanyl, N-(1-methyl-2-(2-thienyl)ethyl-4-
- 23 piperidinyl)-N-phenylpropanamide, its optical isomers, salts, and salts
- 24 of isomers;
- 25 (51) Benzylfentanyl, N-(1-benzyl-4-piperidyl)-N-phenylpropanamide,
- 26 its optical isomers, salts, and salts of isomers;
- 27 (52) Beta-hydroxyfentanyl, N-(1-(2-hydroxy-2-phenethyl)-4-
- 28 piperidinyl)-N-phenylpropanamide, its optical isomers, salts, and salts
- 29 of isomers;
- 30 (53) Beta-hydroxy-3-methylfentanyl, (other name: N-(1-(2-hydroxy-2-
- 31 phenethyl)-3-methyl-4-piperidinyl)-N-phenylpropanamide), its optical and

1 geometric isomers, salts, and salts of isomers;

2 (54) 3-methylthiofentanyl, N-(3-methyl-1-(2-thienyl)ethyl-4-
3 piperidinyl)-N-phenylpropanamide, its optical and geometric isomers,
4 salts, and salts of isomers;

5 (55) N-(1-(2-thienyl)methyl-4-piperidyl)-N-phenylpropanamide
6 (thenylfentanyl), its optical isomers, salts, and salts of isomers;

7 (56) Thiofentanyl, N-phenyl-N-(1-(2-thienyl)ethyl-4-piperidinyl)-
8 propanamide, its optical isomers, salts, and salts of isomers;

9 (57) Para-fluorofentanyl, N-(4-fluorophenyl)-N-(1-(2-phenethyl)-4-
10 piperidinyl)propanamide, its optical isomers, salts, and salts of
11 isomers; ~~and~~

12 (58) U-47700, 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-
13 methylbenzamide; ~~-~~

14 (59) 4-Fluoroisobutyryl Fentanyl;

15 (60) Acetyl Fentanyl;

16 (61) Acyryloylfentanyl;

17 (62) AH-7921; 3, 4-dichloro-N-[(1-dimethylamino) cyclohexylmethyl]
18 benzamide;

19 (63) Butyryl fentanyl;

20 (64) Cyclopentyl fentanyl;

21 (65) Cyclopropyl fentanyl;

22 (66) Furanyl fentanyl;

23 (67) Isobutyryl fentanyl;

24 (68) Isotonitazene;

25 (69) Methoxyacetyl fentanyl;

26 (70) MT-45; 1-cyclohexenyl-4-(1,2-diphenylethyl) piperazine;

27 (71) Tetrahydrofuranyl fentanyl;

28 (72) 2-fluorofentanyl; N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-
29 yl) propionamide;

30 (73) Ocfentanil;

31 (74) ortho-Fluorofentanyl;

- 1 (75) Para-chloroisobutyryl fentanyl;
- 2 (76) para-Fluorobutyryl Fentanyl; and
- 3 (77) Valeryl fentanyl.

4 (b) Any of the following opium derivatives, their salts, isomers,
5 and salts of isomers, unless specifically excepted, whenever the
6 existence of such salts, isomers, and salts of isomers is possible within
7 the specific chemical designation:

- 8 (1) Acetorphine;
- 9 (2) Acetyldihydrocodeine;
- 10 (3) Benzylmorphine;
- 11 (4) Codeine methylbromide;
- 12 (5) Codeine-N-Oxide;
- 13 (6) Cyprenorphine;
- 14 (7) Desomorphine;
- 15 (8) Dihydromorphine;
- 16 (9) Drotebanol;
- 17 (10) Etorphine, except hydrochloride salt;
- 18 (11) Heroin;
- 19 (12) Hydromorphanol;
- 20 (13) Methyldesorphine;
- 21 (14) Methyldihydromorphine;
- 22 (15) Morphine methylbromide;
- 23 (16) Morphine methylsulfonate;
- 24 (17) Morphine-N-Oxide;
- 25 (18) Myrophine;
- 26 (19) Nicocodeine;
- 27 (20) Nicomorphine;
- 28 (21) Normorphine;
- 29 (22) Pholcodine; and
- 30 (23) Thebacon.

31 (c) Any material, compound, mixture, or preparation which contains

1 any quantity of the following hallucinogenic substances, their salts,
2 isomers, and salts of isomers, unless specifically excepted, whenever the
3 existence of such salts, isomers, and salts of isomers is possible within
4 the specific chemical designation, and, for purposes of this subdivision
5 only, isomer shall include the optical, position, and geometric isomers:

6 (1) Bufotenine. Trade and other names shall include, but are not
7 limited to: 3-(beta-Dimethylaminoethyl)-5-hydroxyindole; 3-(2-
8 dimethylaminoethyl)-5-indolol; N,N-dimethylserotonin; 5-hydroxy-N,N-
9 dimethyltryptamine; and mappine;

10 (2) 4-bromo-2,5-dimethoxyamphetamine. Trade and other names shall
11 include, but are not limited to: 4-bromo-2,5-dimethoxy-alpha-
12 methylphenethylamine; and 4-bromo-2,5-DMA;

13 (3) 4-methoxyamphetamine. Trade and other names shall include, but
14 are not limited to: 4-methoxy-alpha-methylphenethylamine; and
15 paramethoxyamphetamine, PMA;

16 (4) 4-methyl-2,5-dimethoxyamphetamine. Trade and other names shall
17 include, but are not limited to: 4-methyl-2,5-dimethoxy-alpha-
18 methylphenethylamine; DOM; and STP;

19 (5) Ibogaine. Trade and other names shall include, but are not
20 limited to: 7-Ethyl-6,6beta,7,8,9,10,12,13-octahydro-2-methoxy-6,9-
21 methano-5H-pyrido (1',2':1,2) azepino (5,4-b) indole; and Tabernanthe
22 iboga;

23 (6) Lysergic acid diethylamide;

24 (7) Marijuana;

25 (8) Mescaline;

26 (9) Peyote. Peyote shall mean all parts of the plant presently
27 classified botanically as *Lophophora williamsii* Lemaire, whether growing
28 or not, the seeds thereof, any extract from any part of such plant, and
29 every compound, manufacture, salts, derivative, mixture, or preparation
30 of such plant or its seeds or extracts;

31 (10) Psilocybin;

1 (11) Psilocyn;

2 (12) Tetrahydrocannabinols, including, but not limited to, synthetic
3 equivalents of the substances contained in the plant or in the resinous
4 extractives of cannabis, sp. or synthetic substances, derivatives, and
5 their isomers with similar chemical structure and pharmacological
6 activity such as the following: Delta 1 cis or trans tetrahydrocannabinol
7 and their optical isomers, excluding dronabinol in a drug product
8 approved by the federal Food and Drug Administration; Delta 6 cis or
9 trans tetrahydrocannabinol and their optical isomers; and Delta 3,4 cis
10 or trans tetrahydrocannabinol and its optical isomers. Since nomenclature
11 of these substances is not internationally standardized, compounds of
12 these structures shall be included regardless of the numerical
13 designation of atomic positions covered. Tetrahydrocannabinols does not
14 include cannabidiol contained in a drug product approved by the federal
15 Food and Drug Administration;

16 (13) N-ethyl-3-piperidyl benzilate;

17 (14) N-methyl-3-piperidyl benzilate;

18 (15) Thiophene analog of phencyclidine. Trade and other names shall
19 include, but are not limited to: 1-(1-(2-thienyl)-cyclohexyl)-piperidine;
20 2-thienyl analog of phencyclidine; TCP; and TCP;

21 (16) Hashish or concentrated cannabis;

22 (17) Parahexyl. Trade and other names shall include, but are not
23 limited to: 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
24 dibenzo(b,d)pyran; and Synhexyl;

25 (18) Ethylamine analog of phencyclidine. Trade and other names shall
26 include, but are not limited to: N-ethyl-1-phenylcyclohexylamine; (1-
27 phenylcyclohexyl)ethylamine; N-(1-phenylcyclohexyl)ethylamine;
28 cyclohexamine; and PCE;

29 (19) Pyrrolidine analog of phencyclidine. Trade and other names
30 shall include, but are not limited to: 1-(1-phenylcyclohexyl)-
31 pyrrolidine; PCPy; and PHP;

1 (20) Alpha-ethyltryptamine. Some trade or other names: etryptamine;
2 Monase; alpha-ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl) indole;
3 alpha-ET; and AET;

4 (21) 2,5-dimethoxy-4-ethylamphet-amine; and DOET;

5 (22) 1-(1-(2-thienyl)cyclohexyl)pyrrolidine; and TCPy;

6 (23) Alpha-methyltryptamine, which is also known as AMT;

7 (24) *Salvia divinorum* or Salvinorin A. *Salvia divinorum* or
8 Salvinorin A includes all parts of the plant presently classified
9 botanically as *Salvia divinorum*, whether growing or not, the seeds
10 thereof, any extract from any part of such plant, and every compound,
11 manufacture, derivative, mixture, or preparation of such plant, its
12 seeds, or its extracts, including salts, isomers, and salts of isomers
13 whenever the existence of such salts, isomers, and salts of isomers is
14 possible within the specific chemical designation;

15 (25) Any material, compound, mixture, or preparation containing any
16 quantity of synthetically produced cannabinoids as listed in subdivisions
17 (A) through (L) of this subdivision, including their salts, isomers,
18 salts of isomers, and nitrogen, oxygen, or sulfur-heterocyclic analogs,
19 unless specifically excepted elsewhere in this section. Since
20 nomenclature of these synthetically produced cannabinoids is not
21 internationally standardized and may continually evolve, these structures
22 or compounds of these structures shall be included under this
23 subdivision, regardless of their specific numerical designation of atomic
24 positions covered, so long as it can be determined through a recognized
25 method of scientific testing or analysis that the substance contains
26 properties that fit within one or more of the following categories:

27 (A) Tetrahydrocannabinols: Meaning tetrahydrocannabinols naturally
28 contained in a plant of the genus *cannabis* (*cannabis* plant), as well as
29 synthetic equivalents of the substances contained in the plant, or in the
30 resinous extractives of *cannabis*, sp. and/or synthetic substances,
31 derivatives, and their isomers with similar chemical structure and

1 pharmacological activity such as the following: Delta 1 cis or trans
2 tetrahydrocannabinol, and their optical isomers; Delta 6 cis or trans
3 tetrahydrocannabinol, and their optical isomers; Delta 3,4 cis or trans
4 tetrahydrocannabinol, and its optical isomers. This subdivision does not
5 include cannabidiol contained in a drug product approved by the federal
6 Food and Drug Administration;

7 (B) Naphthoylindoles: Any compound containing a 3-(1-
8 naphthoyl)indole structure with substitution at the nitrogen atom of the
9 indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
10 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
11 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
12 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
13 tetrahydropyranylmethyl group, whether or not further substituted in or
14 on any of the listed ring systems to any extent;

15 (C) Naphthylmethylindoles: Any compound containing a 1 H-indol-3-
16 yl-(1-naphthyl)methane structure with substitution at the nitrogen atom
17 of the indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
18 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
19 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
20 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
21 tetrahydropyranylmethyl group, whether or not further substituted in or
22 on any of the listed ring systems to any extent;

23 (D) Naphthoylpyrroles: Any compound containing a 3-(1-
24 naphthoyl)pyrrole structure with substitution at the nitrogen atom of the
25 pyrrole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
26 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
27 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
28 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
29 tetrahydropyranylmethyl group, whether or not further substituted in or
30 on any of the listed ring systems to any extent;

31 (E) Naphthylideneindenes: Any compound containing a

1 naphthylideneindene structure with substitution at the 3-position of the
2 indene ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
3 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
4 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
5 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
6 tetrahydropyranylmethyl group, whether or not further substituted in or
7 on any of the listed ring systems to any extent;

8 (F) Phenylacetylindoles: Any compound containing a 3-
9 phenylacetylindole structure with substitution at the nitrogen atom of
10 the indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
11 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
12 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
13 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
14 tetrahydropyranylmethyl group, whether or not further substituted in or
15 on any of the listed ring systems to any extent;

16 (G) Cyclohexylphenols: Any compound containing a 2-(3-
17 hydroxycyclohexyl)phenol structure with substitution at the 5-position of
18 the phenolic ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
19 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
20 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
21 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
22 tetrahydropyranylmethyl group, whether or not substituted in or on any of
23 the listed ring systems to any extent;

24 (H) Benzoylindoles: Any compound containing a 3-(benzoyl)indole
25 structure with substitution at the nitrogen atom of the indole ring by an
26 alkyl, haloalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl,
27 cycloalkylethyl, 2-(4-morpholinyl)ethyl group, cyanoalkyl, 1-(N-methyl-2-
28 piperidinyl)methyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
29 morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not
30 further substituted in or on any of the listed ring systems to any
31 extent;

1 (I) Adamantoylindoles: Any compound containing a 3-adamantoylindole
2 structure with substitution at the nitrogen atom of the indole ring by an
3 alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl, benzyl,
4 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl,
5 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
6 morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not
7 further substituted in or on any of the listed ring systems to any
8 extent;

9 (J) Tetramethylcyclopropanoylindoles: Any compound containing a 3-
10 tetramethylcyclopropanoylindole structure with substitution at the
11 nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl,
12 alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-
13 methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
14 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
15 tetrahydropyranylmethyl group, whether or not further substituted in or
16 on any of the listed ring systems to any extent;

17 (K) Indole carboxamides: Any compound containing a 1-indole-3-
18 carboxamide structure with substitution at the nitrogen atom of the
19 indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl,
20 benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-
21 piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
22 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
23 tetrahydropyranylmethyl group, substitution at the carboxamide group by
24 an alkyl, methoxy, benzyl, propionaldehyde, adamantyl, 1-naphthyl,
25 phenyl, aminooxoalkyl group, or quinolinyl group, whether or not further
26 substituted in or on any of the listed ring systems to any extent or to
27 the adamantyl, 1-naphthyl, phenyl, aminooxoalkyl, benzyl, or
28 propionaldehyde groups to any extent;

29 (L) Indole carboxylates: Any compound containing a 1-indole-3-
30 carboxylate structure with substitution at the nitrogen atom of the
31 indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl,

1 benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-
2 piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
3 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
4 tetrahydropyranylmethyl group, substitution at the carboxylate group by
5 an alkyl, methoxy, benzyl, propionaldehyde, adamantyl, 1-naphthyl,
6 phenyl, aminoalkyl group, or quinolinyl group, whether or not further
7 substituted in or on any of the listed ring systems to any extent or to
8 the adamantyl, 1-naphthyl, phenyl, aminoalkyl, benzyl, or
9 propionaldehyde groups to any extent; and

10 (M) Any nonnaturally occurring substance, chemical compound,
11 mixture, or preparation, not specifically listed elsewhere in these
12 schedules and which is not approved for human consumption by the federal
13 Food and Drug Administration, containing or constituting a cannabinoid
14 receptor agonist as defined in section 28-401;

15 (26) Any material, compound, mixture, or preparation containing any
16 quantity of a substituted phenethylamine as listed in subdivisions (A)
17 through (C) of this subdivision, unless specifically excepted, listed in
18 another schedule, or specifically named in this schedule, that is
19 structurally derived from phenylethan-2-amine by substitution on the
20 phenyl ring with a fused methylenedioxy ring, fused furan ring, or a
21 fused tetrahydrofuran ring; by substitution with two alkoxy groups; by
22 substitution with one alkoxy and either one fused furan, tetrahydrofuran,
23 or tetrahydropyran ring system; or by substitution with two fused ring
24 systems from any combination of the furan, tetrahydrofuran, or
25 tetrahydropyran ring systems, whether or not the compound is further
26 modified in any of the following ways:

27 (A) Substitution of the phenyl ring by any halo, hydroxyl, alkyl,
28 trifluoromethyl, alkoxy, or alkylthio groups; (B) substitution at the 2-
29 position by any alkyl groups; or (C) substitution at the 2-amino nitrogen
30 atom with alkyl, dialkyl, benzyl, hydroxybenzyl or methoxybenzyl groups,
31 and including, but not limited to:

- 1 (i) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine, which is also known
2 as 2C-C or 2,5-Dimethoxy-4-chlorophenethylamine;
- 3 (ii) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine, which is also known
4 as 2C-D or 2,5-Dimethoxy-4-methylphenethylamine;
- 5 (iii) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine, which is also known
6 as 2C-E or 2,5-Dimethoxy-4-ethylphenethylamine;
- 7 (iv) 2-(2,5-Dimethoxyphenyl)ethanamine, which is also known as 2C-H
8 or 2,5-Dimethoxyphenethylamine;
- 9 (v) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine, which is also known as
10 2C-I or 2,5-Dimethoxy-4-iodophenethylamine;
- 11 (vi) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine, which is also known
12 as 2C-N or 2,5-Dimethoxy-4-nitrophenethylamine;
- 13 (vii) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine, which is also
14 known as 2C-P or 2,5-Dimethoxy-4-propylphenethylamine;
- 15 (viii) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine, which is
16 also known as 2C-T-2 or 2,5-Dimethoxy-4-ethylthiophenethylamine;
- 17 (ix) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine, which is
18 also known as 2C-T-4 or 2,5-Dimethoxy-4-isopropylthiophenethylamine;
- 19 (x) 2-(4-bromo-2,5-dimethoxyphenyl)ethanamine, which is also known
20 as 2C-B or 2,5-Dimethoxy-4-bromophenethylamine;
- 21 (xi) 2-(2,5-dimethoxy-4-(methylthio)phenyl)ethanamine, which is also
22 known as 2C-T or 4-methylthio-2,5-dimethoxyphenethylamine;
- 23 (xii) 1-(2,5-dimethoxy-4-iodophenyl)-propan-2-amine, which is also
24 known as DOI or 2,5-Dimethoxy-4-iodoamphetamine;
- 25 (xiii) 1-(4-Bromo-2,5-dimethoxyphenyl)-2-aminopropane, which is also
26 known as DOB or 2,5-Dimethoxy-4-bromoamphetamine;
- 27 (xiv) 1-(4-chloro-2,5-dimethoxy-phenyl)propan-2-amine, which is also
28 known as DOC or 2,5-Dimethoxy-4-chloroamphetamine;
- 29 (xv) 2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-
30 methoxyphenyl)methyl]ethanamine, which is also known as 2C-B-NBOMe; 25B-
31 NBOMe or 2,5-Dimethoxy-4-bromo-N-(2-methoxybenzyl)phenethylamine;

- 1 (xvi) 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-
2 methoxyphenyl)methyl]ethanamine, which is also known as 2C-I-NBOMe; 25I-
3 NBOMe or 2,5-Dimethoxy-4-iodo-N-(2-methoxybenzyl)phenethylamine;
- 4 (xvii) N-(2-Methoxybenzyl)-2-(3,4,5-trimethoxyphenyl)ethanamine,
5 which is also known as Mescaline-NBOMe or 3,4,5-trimethoxy-N-(2-
6 methoxybenzyl)phenethylamine;
- 7 (xviii) 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-
8 methoxyphenyl)methyl]ethanamine, which is also known as 2C-C-NBOMe; or
9 25C-NBOMe or 2,5-Dimethoxy-4-chloro-N-(2-methoxybenzyl)phenethylamine;
- 10 (xix) 2-(7-Bromo-5-methoxy-2,3-dihydro-1-benzofuran-4-yl)ethanamine,
11 which is also known as 2CB-5-hemiFLY;
- 12 (xx) 2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4-
13 yl)ethanamine, which is also known as 2C-B-FLY;
- 14 (xxi) 2-(10-Bromo-2,3,4,7,8,9-hexahydropyrano[2,3-g]chromen-5-
15 yl)ethanamine, which is also known as 2C-B-butterFLY;
- 16 (xxii) N-(2-Methoxybenzyl)-1-(8-bromo-2,3,6,7- tetrahydrobenzo[1,2-
17 b:4,5-b']difuran-4-yl)-2-aminoethane, which is also known as 2C-B-FLY-
18 NBOMe;
- 19 (xxiii) 1-(4-Bromofuro[2,3-f][1]benzofuran-8-yl)propan-2-amine,
20 which is also known as bromo-benzodifuranylisopropylamine or bromo-
21 dragonFLY;
- 22 (xxiv) N-(2-Hydroxybenzyl)-4-iodo-2,5-dimethoxyphenethylamine, which
23 is also known as 2C-INBOH or 25I-NBOH;
- 24 (xxv) 5-(2-Aminopropyl)benzofuran, which is also known as 5-APB;
- 25 (xxvi) 6-(2-Aminopropyl)benzofuran, which is also known as 6-APB;
- 26 (xxvii) 5-(2-Aminopropyl)-2,3-dihydrobenzofuran, which is also known
27 as 5-APDB;
- 28 (xxviii) 6-(2-Aminopropyl)-2,3-dihydrobenzofuran, which is also
29 known as 6-APDB;
- 30 (xxix) 2,5-dimethoxy-amphetamine, which is also known as 2, 5-
31 dimethoxy-a-methylphenethylamine; 2, 5-DMA;

1 (xxx) 2,5-dimethoxy-4-ethylamphetamine, which is also known as DOET;
2 (xxxi) 2,5-dimethoxy-4-(n)-propylthiophenethylamine, which is also
3 known as 2C-T-7;

4 (xxxii) 5-methoxy-3,4-methylenedioxy-amphetamine;

5 (xxxiii) 4-methyl-2,5-dimethoxy-amphetamine, which is also known as
6 4-methyl-2,5-dimethoxy-amethylphenethylamine; DOM and STP;

7 (xxxiv) 3,4-methylenedioxy amphetamine, which is also known as MDA;

8 (xxxv) 3,4-methylenedioxymethamphetamine, which is also known as
9 MDMA;

10 (xxxvi) 3,4-methylenedioxy-N-ethylamphetamine, which is also known
11 as N-ethyl-alpha-methyl-3,4(methylenedioxy)phenethylamine, MDE, MDEA; ~~and~~

12 (xxxvii) 3,4,5-trimethoxy amphetamine; and

13 (xxxviii) n-hydroxy-3,4-Methylenedioxyamphetamine, which is also
14 known as N-hydroxyMDA;

15 (27) Any material, compound, mixture, or preparation containing any
16 quantity of a substituted tryptamine unless specifically excepted, listed
17 in another schedule, or specifically named in this schedule, that is
18 structurally derived from 2-(1H-indol-3-yl)ethanamine, which is also
19 known as tryptamine, by mono- or di-substitution of the amine nitrogen
20 with alkyl or alkenyl groups or by inclusion of the amino nitrogen atom
21 in a cyclic structure whether or not the compound is further substituted
22 at the alpha position with an alkyl group or whether or not further
23 substituted on the indole ring to any extent with any alkyl, alkoxy,
24 halo, hydroxyl, or acetoxy groups, and including, but not limited to:

25 (A) 5-methoxy-N,N-diallyltryptamine, which is also known as 5-MeO-
26 DALT;

27 (B) 4-acetoxy-N,N-dimethyltryptamine, which is also known as 4-AcO-
28 DMT or OAcetylpsilocin;

29 (C) 4-hydroxy-N-methyl-N-ethyltryptamine, which is also known as 4-
30 HO-MET;

31 (D) 4-hydroxy-N,N-diisopropyltryptamine, which is also known as 4-

1 HO-DIPT;

2 (E) 5-methoxy-N-methyl-N-isopropyltryptamine, which is also known as
3 5-MeOMiPT;

4 (F) 5-Methoxy-N,N-Dimethyltryptamine, which is also known as 5-MeO-
5 DMT;

6 (G) 5-methoxy-N,N-diisopropyltryptamine, which is also known as 5-
7 MeO-DiPT;

8 (H) Diethyltryptamine, which is also known as N,N-Diethyltryptamine,
9 DET; and

10 (I) Dimethyltryptamine, which is also known as DMT; and

11 (28)(A) Any substance containing any quantity of the following
12 materials, compounds, mixtures, or structures:

13 (i) 3,4-methylenedioxymethcathinone, or bk-MDMA, or methydone;

14 (ii) 3,4-methylenedioxypyrovalerone, or MDPV;

15 (iii) 4-methylmethcathinone, or 4-MMC, or mephedrone;

16 (iv) 4-methoxymethcathinone, or bk-PMMA, or PMMC, or methedrone;

17 (v) Fluoromethcathinone, or FMC;

18 (vi) Naphthylpyrovalerone, or naphyrone; or

19 (vii) Beta-keto-N-methylbenzodioxolylpropylamine or bk-MBDB or
20 butylone; or

21 (B) Unless listed in another schedule, any substance which contains
22 any quantity of any material, compound, mixture, or structure, other than
23 bupropion, that is structurally derived by any means from 2-
24 aminopropan-1-one by substitution at the 1-position with either phenyl,
25 naphthyl, or thiophene ring systems, whether or not the compound is
26 further modified in any of the following ways:

27 (i) Substitution in the ring system to any extent with alkyl,
28 alkoxy, alkylenedioxy, haloalkyl, hydroxyl, or halide substituents,
29 whether or not further substituted in the ring system by one or more
30 other univalent substituents;

31 (ii) Substitution at the 3-position with an acyclic alkyl

1 substituent; or

2 (iii) Substitution at the 2-amino nitrogen atom with alkyl or
3 dialkyl groups, or by inclusion of the 2-amino nitrogen atom in a cyclic
4 structure.

5 (d) Unless specifically excepted or unless listed in another
6 schedule, any material, compound, mixture, or preparation which contains
7 any quantity of the following substances having a depressant effect on
8 the central nervous system, including its salts, isomers, and salts of
9 isomers whenever the existence of such salts, isomers, and salts of
10 isomers is possible within the specific chemical designation:

11 (1) Mecloqualone;

12 (2) Methaqualone; and

13 (3) Gamma-Hydroxybutyric Acid. Some other names include: GHB; Gamma-
14 hydroxybutyrate; 4-Hydroxybutyrate; 4-Hydroxybutanoic Acid; Sodium
15 Oxybate; and Sodium Oxybutyrate.

16 (e) Unless specifically excepted or unless listed in another
17 schedule, any material, compound, mixture, or preparation which contains
18 any quantity of the following substances having a stimulant effect on the
19 central nervous system, including its salts, isomers, and salts of
20 isomers:

21 (1) Fenethylline;

22 (2) N-ethylamphetamine;

23 (3) Aminorex; aminoxaphen; 2-amino-5-phenyl-2-oxazoline; or 4,5-
24 dihydro-5-phenyl-2-oxazolamine;

25 (4) Cathinone; 2-amino-1-phenyl-1-propanone; alpha-
26 aminopropiophenone; 2-aminopropiophenone; and norephedrone;

27 (5) Methcathinone, its salts, optical isomers, and salts of optical
28 isomers. Some other names: 2-(methylamino)-propiofenone; alpha-
29 (methylamino)propiofenone; 2-(methylamino)-1-phenylpropan-1-one; alpha-
30 N-methylaminopropiophenone; methylcathinone; monomethylpropion;
31 ephedrone; N-methylcathinone; AL-464; AL-422; AL-463; and UR1432; and 4-

1 MEC;

2 (6) (+/-)-cis-4-methylaminorex; and (+/-)-cis-4,5-dihydro-4-methyl-5-
3 phenyl-2-oxazolamine;

4 (7) N,N-dimethylamphetamine; N,N-alpha-trimethyl-benzeneethanamine;
5 and N,N-alpha-trimethylphenethylamine; and

6 (8) Benzylpiperazine, 1-benzylpiperazine.

7 (f) Any controlled substance analogue to the extent intended for
8 human consumption.

9 Schedule II

10 (a) Any of the following substances except those narcotic drugs
11 listed in other schedules whether produced directly or indirectly by
12 extraction from substances of vegetable origin, independently by means of
13 chemical synthesis, or by combination of extraction and chemical
14 synthesis:

15 (1) Opium and opiate, and any salt, compound, derivative, or
16 preparation of opium or opiate, excluding apomorphine, buprenorphine,
17 thebaine-derived butorphanol, dextrophan, nalbuphine, nalmefene,
18 naloxone, and naltrexone and their salts, but including the following:

19 (A) Raw opium;

20 (B) Opium extracts;

21 (C) Opium fluid;

22 (D) Powdered opium;

23 (E) Granulated opium;

24 (F) Tincture of opium;

25 (G) Codeine;

26 (H) Ethylmorphine;

27 (I) Etorphine hydrochloride;

28 (J) Hydrocodone;

29 (K) Hydromorphone;

30 (L) Metopon;

31 (M) Morphine;

- 1 (N) Oxycodone;
- 2 (O) Oxymorphone;
- 3 (P) Oripavine;
- 4 (Q) Thebaine; and
- 5 (R) Dihydroetorphine;
- 6 (2) Any salt, compound, derivative, or preparation thereof which is
- 7 chemically equivalent to or identical with any of the substances referred
- 8 to in subdivision (1) of this subdivision, except that these substances
- 9 shall not include the isoquinoline alkaloids of opium;
- 10 (3) Opium poppy and poppy straw;
- 11 (4) Coca leaves and any salt, compound, derivative, or preparation
- 12 of coca leaves, and any salt, compound, derivative, or preparation
- 13 thereof which is chemically equivalent to or identical with any of these
- 14 substances, including cocaine or ecgonine and its salts, optical isomers,
- 15 and salts of optical isomers, except that the substances shall not
- 16 include decocainized coca leaves or extractions which do not contain
- 17 cocaine or ecgonine; and
- 18 (5) Concentrate of poppy straw, the crude extract of poppy straw in
- 19 either liquid, solid, or powder form which contains the phenanthrene
- 20 alkaloids of the opium poppy.
- 21 (b) Unless specifically excepted or unless in another schedule any
- 22 of the following opiates, including their isomers, esters, ethers, salts,
- 23 and salts of their isomers, esters, and ethers whenever the existence of
- 24 such isomers, esters, ethers, and salts is possible within the specific
- 25 chemical designation, dextrorphan excepted:
- 26 (1) Alphaprodine;
- 27 (2) Anileridine;
- 28 (3) Bezitramide;
- 29 (4) Diphenoxylate;
- 30 (5) Fentanyl;
- 31 (6) Isomethadone;

- 1 (7) Levomethorphan;
- 2 (8) Levorphanol;
- 3 (9) Metazocine;
- 4 (10) Methadone;
- 5 (11) Methadone-intermediate, 4-cyano-2-dimethylamino-4,4-diphenyl
- 6 butane;
- 7 (12) Moramide-intermediate, 2-methyl-3-morpholino-1,1-
- 8 diphenylpropane-carboxylic acid;
- 9 (13) Norfentanyl (N-phenyl-N-peperidin-4-yl) propionamide;
- 10 (14) Oliceridine;
- 11 (15) (13) Pethidine or meperidine;
- 12 (16) (14) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-
- 13 phenylpiperidine;
- 14 (17) (15) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-
- 15 carboxylate;
- 16 (18) (16) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-
- 17 carboxylic acid;
- 18 (19) (17) Phenazocine;
- 19 (20) (18) Piminodine;
- 20 (21) (19) Racemethorphan;
- 21 (22) (20) Racemorphan;
- 22 (23) (21) Dihydrocodeine;
- 23 (24) (22) Bulk Propoxyphene in nondosage forms;
- 24 (25) (23) Sufentanil;
- 25 (26) (24) Alfentanil;
- 26 (27) (25) Levo-alphaacetylmethadol which is also known as levo-alpha-
- 27 acetylmethadol, levomethadyl acetate, and LAAM;
- 28 (28) (26) Carfentanil;
- 29 (29) (27) Remifentanil;
- 30 (30) (28) Tapentadol; and
- 31 (31) (29) Thiafentanil.

1 (c) Any material, compound, mixture, or preparation which contains
2 any quantity of the following substances having a potential for abuse
3 associated with a stimulant effect on the central nervous system:

4 (1) Amphetamine, its salts, optical isomers, and salts of its
5 optical isomers;

6 (2) Phenmetrazine and its salts;

7 (3) Methamphetamine, its salts, isomers, and salts of its isomers;

8 (4) Methylphenidate; and

9 (5) Lisdexamfetamine, its salts, isomers, and salts of its isomers.

10 (d) Any material, compound, mixture, or preparation which contains
11 any quantity of the following substances having a potential for abuse
12 associated with a depressant effect on the central nervous system,
13 including their salts, isomers, and salts of isomers whenever the
14 existence of such salts, isomers, and salts of isomers is possible within
15 the specific chemical designations:

16 (1) Amobarbital;

17 (2) Secobarbital;

18 (3) Pentobarbital;

19 (4) Phencyclidine; and

20 (5) Glutethimide.

21 (e) Hallucinogenic substances known as:

22 (1) Nabilone. Another name for nabilone: (+/-)-trans-3-(1,1-
23 dimethylheptyl)- 6,6a,7,8,10,10a-Hexahydro-1-hydroxy-6,6-dimethyl-9H-
24 dibenzo(b,d)pyran-9-one; and

25 (2) Dronabinol in an oral solution in a drug product approved by the
26 federal Food and Drug Administration.

27 (f) Unless specifically excepted or unless listed in another
28 schedule, any material, compound, mixture, or preparation which contains
29 any quantity of the following substances:

30 (1) Immediate precursor to amphetamine and methamphetamine:
31 Phenylacetone. Trade and other names shall include, but are not limited

1 to: Phenyl-2-propanone; P2P; benzyl methyl ketone; and methyl benzyl
2 ketone;

3 (2) Immediate precursors to phencyclidine, PCP:

4 (A) 1-phenylcyclohexylamine; or

5 (B) 1-piperidinocyclohexanecarbonitrile, PCC; or

6 (3) Immediate precursor to fentanyl; 4-anilino-N-phenethylpiperidine
7 (ANPP) ~~4-anilino-N-phenethyl-4-piperidine (ANNPP)~~.

8 Schedule III

9 (a) Any material, compound, mixture, or preparation which contains
10 any quantity of the following substances having a potential for abuse
11 associated with a stimulant effect on the central nervous system,
12 including their salts, isomers, whether optical, position, or geometric,
13 and salts of such isomers whenever the existence of such salts, isomers,
14 and salts of isomers is possible within the specific chemical
15 designation:

16 (1) Benzphetamine;

17 (2) Chlorphentermine;

18 (3) Clortermine; and

19 (4) Phendimetrazine.

20 (b) Any material, compound, mixture, or preparation which contains
21 any quantity of the following substances having a potential for abuse
22 associated with a depressant effect on the central nervous system:

23 (1) Any substance which contains any quantity of a derivative of
24 barbituric acid or any salt of a derivative of barbituric acid, except
25 those substances which are specifically listed in other schedules of this
26 section;

27 (2) Aprobarbital;

28 (3) Butabarbital;

29 (4) Butalbital;

30 (5) Butethal;

31 (6) Butobarbital;

- 1 (7) ~~(2)~~ Chlorhexadol;
- 2 (8) ~~(3)~~ Embutramide;
- 3 (9) ~~(4)~~ Lysergic acid;
- 4 (10) ~~(5)~~ Lysergic acid amide;
- 5 (11) ~~(6)~~ Methyprylon;
- 6 (12) ~~(7)~~ Perampanel;
- 7 (13) ~~(8)~~ Secbutabarbital;
- 8 (14) ~~(9)~~ Sulfondiethylmethane;
- 9 (15) ~~(10)~~ Sulfonethylmethane;
- 10 (16) ~~(11)~~ Sulfonmethane;
- 11 (17) ~~(12)~~ Nalorphine;
- 12 (18) ~~(13)~~ Talbutal;
- 13 (19) ~~(14)~~ Thiamylal;
- 14 (20) ~~(15)~~ Thiopental;
- 15 (21) ~~(16)~~ Vinbarbital;
- 16 (22) ~~(17)~~ Any compound, mixture, or preparation containing
- 17 amobarbital, secobarbital, pentobarbital, or any salt thereof and one or
- 18 more other active medicinal ingredients which are not listed in any
- 19 schedule;
- 20 (23) ~~(18)~~ Any suppository dosage form containing amobarbital,
- 21 secobarbital, pentobarbital, or any salt of any of these drugs and
- 22 approved by the federal Food and Drug Administration for marketing only
- 23 as a suppository;
- 24 (24) ~~(19)~~ Any drug product containing gamma-hydroxybutyric acid,
- 25 including its salts, isomers, and salts of isomers, for which an
- 26 application is approved under section 505 of the Federal Food, Drug, and
- 27 Cosmetic Act, 21 U.S.C. 355, as such section existed on January 1, 2014;
- 28 (25) ~~(20)~~ Ketamine, its salts, isomers, and salts of isomers. Some
- 29 other names for ketamine: (+/-)-2-(2-chlorophenyl)-2-(methylamino)-
- 30 cyclohexanone; and
- 31 (26) ~~(21)~~ Tiletamine and zolazepam or any salt thereof. Trade or

1 other names for a tiletamine-zolazepam combination product shall include,
2 but are not limited to: telazol. Trade or other names for tiletamine
3 shall include, but are not limited to: 2-(ethylamino)-2-(2-thienyl)-
4 cyclohexanone. Trade or other names for zolazepam shall include, but are
5 not limited to: 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-
6 trimethylpyrazolo-(3,4-e) (1,4)-diazepin-7(1H)-one, and flupyrzapon.

7 (c) Unless specifically excepted or unless listed in another
8 schedule:

9 (1) Any material, compound, mixture, or preparation containing
10 limited quantities of any of the following narcotic drugs, or any salts
11 calculated as the free anhydrous base or alkaloid, in limited quantities
12 as set forth below:

13 (A) Not more than one and eight-tenths grams of codeine per one
14 hundred milliliters or not more than ninety milligrams per dosage unit,
15 with an equal or greater quantity of an isoquinoline alkaloid of opium;

16 (B) Not more than one and eight-tenths grams of codeine per one
17 hundred milliliters or not more than ninety milligrams per dosage unit,
18 with one or more active, nonnarcotic ingredients in recognized
19 therapeutic amounts;

20 (C) Not more than one and eight-tenths grams of dihydrocodeine per
21 one hundred milliliters or not more than ninety milligrams per dosage
22 unit, with one or more active, nonnarcotic ingredients in recognized
23 therapeutic amounts;

24 (D) Not more than three hundred milligrams of ethylmorphine per one
25 hundred milliliters or not more than fifteen milligrams per dosage unit,
26 with one or more active, nonnarcotic ingredients in recognized
27 therapeutic amounts;

28 (E) Not more than five hundred milligrams of opium per one hundred
29 milliliters or per one hundred grams, or not more than twenty-five
30 milligrams per dosage unit, with one or more active, nonnarcotic
31 ingredients in recognized therapeutic amounts; and

1 (F) Not more than fifty milligrams of morphine per one hundred
2 milliliters or per one hundred grams with one or more active, nonnarcotic
3 ingredients in recognized therapeutic amounts; and

4 (2) Any material, compound, mixture, or preparation containing any
5 of the following narcotic drug or its salts, as set forth below:

6 (A) Buprenorphine.

7 (d) Unless contained on the list of exempt anabolic steroids of the
8 Drug Enforcement Administration of the United States Department of
9 Justice as the list existed on January 31, 2021 ~~November 9, 2017~~, any
10 anabolic steroid, which shall include any material, compound, mixture, or
11 preparation containing any quantity of the following substances,
12 including its salts, isomers, and salts of isomers whenever the existence
13 of such salts of isomers is possible within the specific chemical
14 designation:

15 (1) 3-beta,17-dihydroxy-5a-androstane;

16 (2) 3-alpha,17-beta-dihydroxy-5a-androstane;

17 (3) 5-alpha-androstan-3,17-dione;

18 (4) 1-androstenediol (3-beta,17-beta-dihydroxy-5-alpha-androst-1-
19 ene);

20 (5) 1-androstenediol (3-alpha,17-beta-dihydroxy-5-alpha-androst-1-
21 ene);

22 (6) 4-androstenediol (3-beta,17-beta-dihydroxy-androst-5-ene);

23 (7) 5-androstenediol (3-beta,17-beta-dihydroxy-androst-5-ene);

24 (8) 1-androstenedione ([5-alpha]-androst-1-en-3,17-dione);

25 (9) 4-androstenedione (androst-4-en-3,17-dione);

26 (10) 5-androstenedione (androst-5-en-3,17-dione);

27 (11) Bolasterone (7-alpha,17-alpha-dimethyl-17-beta-
28 hydroxyandrost-4-en-3-one);

29 (12) Boldenone (17-beta-hydroxyandrost-1,4-diene-3-one);

30 (13) Boldione (androsta-1,4-diene-3,17-3-one);

31 (14) Calusterone (7-beta,17-alpha-dimethyl-17-beta-hydroxyandrost-4-

- 1 en-3-one);
- 2 (15) Clostebol (4-chloro-17-beta-hydroxyandrost-4-en-3-one);
- 3 (16) Dehydrochloromethyltestosterone (4-chloro-17-beta-hydroxy-17-
- 4 alpha-methyl-androst-1,4-dien-3-one);
- 5 (17) Desoxymethyltestosterone (17-alpha-methyl-5-alpha-androst-2-
- 6 en-17-beta-ol) (a.k.a. 'madol');
- 7 (18) Delta-1-Dihydrotestosterone (a.k.a. '1-testosterone')(17-beta-
- 8 hydroxy-5-alpha-androst-1-en-3-one);
- 9 (19) 4-Dihydrotestosterone (17-beta-hydroxy-androstan-3-one);
- 10 (20) Drostanolone (17-beta-hydroxy-2-alpha-methyl-5-alpha-
- 11 androstan-3-one);
- 12 (21) Ethylestrenol (17-alpha-ethyl-17-beta-hydroxyestr-4-ene);
- 13 (22) Fluoxymesterone (9-fluoro-17-alpha-methyl-11-beta,17-beta-
- 14 dihydroxyandrost-4-en-3-one);
- 15 (23) Formebolone (formebolone); (2-formyl-17-alpha-methyl-11-
- 16 alpha,17-beta-dihydroxyandrost-1,4-dien-3-one);
- 17 (24) Furazabol (17-alpha-methyl-17-beta-hydroxyandrostano[2,3-c]-
- 18 furazan);
- 19 (25) 13-beta-ethyl-17-beta-hydroxygon-4-en-3-one;
- 20 (26) 4-hydroxytestosterone (4,17-beta-dihydroxy-androst-4-en-3-one);
- 21 (27) 4-hydroxy-19-nortestosterone (4,17-beta-dihydroxy-estr-4-en-3-
- 22 one);
- 23 (28) Mestanolone (17-alpha-methyl-17-beta-hydroxy-5-androstan-3-
- 24 one);
- 25 (29) Mesterolone (17-alpha-methyl-17-beta-hydroxy-5-androstan-3-
- 26 one);
- 27 (30) Methandienone (17-alpha-methyl-17-beta-hydroxyandrost-1,4-
- 28 dien-3-one);
- 29 (31) Methandriol (17-alpha-methyl-3-beta,17-beta-dihydroxyandrost-5-
- 30 ene);
- 31 (32) Methasterone (2-alpha,17-alpha-dimethyl-5-alpha-androstan-17-

- 1 beta-ol-3-one);
- 2 (33) Methenolone (1-methyl-17-beta-hydroxy-5-alpha-androst-1-en-3-
- 3 one);
- 4 (34) 17-alpha-methyl-3-beta,17-beta-dihydroxy-5a-androstane;
- 5 (35) 17-alpha-methyl-3-alpha,17-beta-dihydroxy-5a-androstane;
- 6 (36) 17-alpha-methyl-3-beta,17-beta-dihydroxyandrost-4-ene;
- 7 (37) 17-alpha-methyl-4-hydroxynandrolone (17-alpha-methyl-4-
- 8 hydroxy-17-beta-hydroxyestr-4-en-3-one);
- 9 (38) Methyldienolone (17-alpha-methyl-17-beta-hydroxyestra-4,9(10)-
- 10 dien-3-one);
- 11 (39) Methyltrienolone (17-alpha-methyl-17-beta-hydroxyestra-4,9,11-
- 12 trien-3-one);
- 13 (40) Methyltestosterone (17-alpha-methyl-17-beta-hydroxyandrost-4-
- 14 en-3-one);
- 15 (41) Mibolerone (7-alpha,17-alpha-dimethyl-17-beta-hydroxyestr-4-
- 16 en-3-one);
- 17 (42) 17-alpha-methyl-delta-1-dihydrotestosterone (17-beta-
- 18 hydroxy-17-alpha-methyl-5-alpha-androst-1-en-3-one) (a.k.a. '17-alpha-
- 19 methyl-1-testosterone');
- 20 (43) Nandrolone (17-beta-hydroxyestr-4-en-3-one);
- 21 (44) 19-nor-4-androstenediol (3-beta, 17-beta-dihydroxyestr-4-ene);
- 22 (45) 19-nor-4-androstenediol (3-alpha, 17-beta-dihydroxyestr-4-ene);
- 23 (46) 19-nor-5-androstenediol (3-beta, 17-beta-dihydroxyestr-5-ene);
- 24 (47) 19-nor-5-androstenediol (3-alpha, 17-beta-dihydroxyestr-5-ene);
- 25 (48) 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-
- 26 dione);
- 27 (49) 19-nor-4-androstenedione (estr-4-en-3,17-dione);
- 28 (50) 19-nor-5-androstenedione (estr-5-en-3,17-dione);
- 29 (51) Norbolethone (13-beta, 17-alpha-diethyl-17-beta-hydroxygon-4-
- 30 en-3-one);
- 31 (52) Norclostebol (4-chloro-17-beta-hydroxyestr-4-en-3-one);

- 1 (53) Norethandrolone (17-alpha-ethyl-17-beta-hydroxyestr-4-en-3-
2 one);
- 3 (54) Normethandrolone (17-alpha-methyl-17-beta-hydroxyestr-4-en-3-
4 one);
- 5 (55) Oxandrolone (17-alpha-methyl-17-beta-hydroxy-2-oxa-[5-alpha]-
6 androstan-3-one);
- 7 (56) Oxymesterone (17-alpha-methyl-4,17-beta-dihydroxyandrost-4-
8 en-3-one);
- 9 (57) Oxymetholone (17-alpha-methyl-2-hydroxymethylene-17-beta-
10 hydroxy-[5-alpha]-androstan-3-one);
- 11 (58) Prostanazol (17-beta-hydroxy-5-alpha-androstano[3,2-
12 c]pyrazole);
- 13 (59) Stanazolol (17-alpha-methyl-17-beta-hydroxy-[5-alpha]-
14 androst-2-eno[3,2-c]-pyrazole);
- 15 (60) Stenbolone (17-beta-hydroxy-2-methyl-[5-alpha]-androst-1-en-3-
16 one);
- 17 (61) Testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-
18 oic acid lactone);
- 19 (62) Testosterone (17-beta-hydroxyandrost-4-en-3-one);
- 20 (63) Tetrahydrogestrinone (13-beta, 17-alpha-diethyl-17-beta-
21 hydroxygon-4,9,11-trien-3-one);
- 22 (64) Trenbolone (17-beta-hydroxyestr-4,9,11-trien-3-one);—and
- 23 (65) [3,2-c]-furazan-5 alpha-androstane-17 beta-ol;
- 24 (66) [3,2-c]pyrazole-androst-4-en-17 beta-ol;
- 25 (67) 17 alpha-methyl-androst-ene-3,17 beta-diol;
- 26 (68) 17 alpha-methyl-androsta-1,4-diene-3,17 beta-diol;
- 27 (69) 17 alpha-methyl-androstan-3-hydroxyimine-17 beta-ol;
- 28 (70) 17 beta-hydroxy-androstano[2,3-d]isoxazole;
- 29 (71) 17 beta-hydroxy-androstano[3,2-c]isoxazole;
- 30 (72) 18a-homo-3-hydroxy-estra-2,5(10)-dien-17-one;
- 31 (73) 2 alpha, 3 alpha-epithio-17 alpha-methyl-5 alpha-androstan-17

1 beta-ol;

2 (74) 4-chloro-17 alpha-methyl-17 beta-hydroxy-androst-4-en-3-one;

3 (75) 4-chloro-17 alpha-methyl-17 beta-hydroxy-androst-4-en-3,11-

4 dione;

5 (76) 4-chloro-17 alpha-methyl-androst-4-ene-3 beta,17 beta-diol;

6 (77) 4-chloro-17 alpha-methyl-androsta-1,4,diene-3,17 beta-diol;

7 (78) 4-hydroxy-androst-4-ene-3,17-dione;

8 (79) 5 alpha-Androstan-3,6,17-trione;

9 (80) 6-bromo-androst-1,4-diene-3,17-dione;

10 (81) 6-bromo-androstan-3,17-dione;

11 (82) 6 alpha-methyl-androst-4-ene-3,17-dione;

12 (83) Delta 1-dihydrotestosterone;

13 (84) Estra-4,9,11-triene-3,17-dione; and

14 (85) ~~(65)~~ Any salt, ester, or ether of a drug or substance described
15 or listed in this subdivision if the salt, ester, or ether promotes
16 muscle growth.

17 (e) Hallucinogenic substances known as:

18 (1) Dronabinol, synthetic, in sesame oil and encapsulated in a soft
19 gelatin capsule in a drug product approved by the federal Food and Drug
20 Administration. Some other names for dronabinol are (6aR-
21 trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo
22 (b,d)pyran-1-ol or (-)-delta-9-(trans)-tetrahydrocannabinol.

23 Schedule IV

24 (a) Any material, compound, mixture, or preparation which contains
25 any quantity of the following substances, including their salts, isomers,
26 and salts of isomers whenever the existence of such salts, isomers, and
27 salts of isomers is possible within the specific chemical designation:

28 (1) Barbital;

29 (2) Chloral betaine;

30 (3) Chloral hydrate;

31 (4) Chlordiazepoxide, but not including librax (chlordiazepoxide

- 1 hydrochloride and clindinium bromide) or menrium (chlordiazepoxide and
2 water soluble esterified estrogens);
- 3 (5) Clonazepam;
 - 4 (6) Clorazepate;
 - 5 (7) Diazepam;
 - 6 (8) Ethchlorvynol;
 - 7 (9) Ethinamate;
 - 8 (10) Flurazepam;
 - 9 (11) Mebutamate;
 - 10 (12) Meprobamate;
 - 11 (13) Methohexital;
 - 12 (14) Methylphenobarbital;
 - 13 (15) Oxazepam;
 - 14 (16) Paraldehyde;
 - 15 (17) Petrichloral;
 - 16 (18) Phenobarbital;
 - 17 (19) Prazepam;
 - 18 (20) Alprazolam;
 - 19 (21) Bromazepam;
 - 20 (22) Camazepam;
 - 21 (23) Clobazam;
 - 22 (24) Clotiazepam;
 - 23 (25) Cloxazolam;
 - 24 (26) Delorazepam;
 - 25 (27) Estazolam;
 - 26 (28) Ethyl loflazepate;
 - 27 (29) Fludiazepam;
 - 28 (30) Flunitrazepam;
 - 29 (31) Halazepam;
 - 30 (32) Haloxazolam;
 - 31 (33) Ketazolam;

- 1 (34) Loprazolam;
- 2 (35) Lorazepam;
- 3 (36) Lormetazepam;
- 4 (37) Medazepam;
- 5 (38) Nimetazepam;
- 6 (39) Nitrazepam;
- 7 (40) Nordiazepam;
- 8 (41) Oxazolam;
- 9 (42) Pinazepam;
- 10 (43) Temazepam;
- 11 (44) Tetrazepam;
- 12 (45) Triazolam;
- 13 (46) Midazolam;
- 14 (47) Quazepam;
- 15 (48) Zolpidem;
- 16 (49) Dichloralphenazone;
- 17 (50) Zaleplon;
- 18 (51) Zopiclone;
- 19 (52) Fospropofol;
- 20 (53) Alfaxalone;
- 21 (54) Suvorexant; ~~and~~
- 22 (55) Carisoprodol; ~~-~~
- 23 (56) Brexanolone; 3 alpha-hydroxy-5 alpha-pregnan-20-one;
- 24 (57) Lemborexant;
- 25 (58) Solriamfetol; 2-amino-3-phenylpropyl carbamate; and
- 26 (59) Remimazolam.

27 (b) Any material, compound, mixture, or preparation which contains
28 any quantity of the following substance, including its salts, isomers,
29 whether optical, position, or geometric, and salts of such isomers,
30 whenever the existence of such salts, isomers, and salts of isomers is
31 possible: Fenfluramine.

1 (c) Unless specifically excepted or unless listed in another
2 schedule, any material, compound, mixture, or preparation which contains
3 any quantity of the following substances having a stimulant effect on the
4 central nervous system, including their salts, isomers, whether optical,
5 position, or geometric, and salts of such isomers whenever the existence
6 of such salts, isomers, and salts of isomers is possible within the
7 specific chemical designation:

8 (1) Diethylpropion;

9 (2) Phentermine;

10 (3) Pemoline, including organometallic complexes and chelates
11 thereof;

12 (4) Mazindol;

13 (5) Pipradrol;

14 (6) SPA, ((-)-1-dimethylamino- 1,2-diphenylethane);

15 (7) Cathine. Another name for cathine is ((+)-norpseudoephedrine);

16 (8) Fencamfamin;

17 (9) Fenproporex;

18 (10) Mefenorex;

19 (11) Modafinil; and

20 (12) Sibutramine.

21 (d) Unless specifically excepted or unless listed in another
22 schedule, any material, compound, mixture, or preparation which contains
23 any quantity of the following narcotic drugs, or their salts or isomers
24 calculated as the free anhydrous base or alkaloid, in limited quantities
25 as set forth below:

26 (1) Propoxyphene in manufactured dosage forms;

27 (2) Not more than one milligram of difenoxin and not less than
28 twenty-five micrograms of atropine sulfate per dosage unit; and

29 (3) 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its
30 salts, optical and geometric isomers, and salts of these isomers to
31 include: Tramadol.

1 (e) Unless specifically excepted or unless listed in another
2 schedule, any material, compound, mixture, or preparation which contains
3 any quantity of the following substance, including its salts:

4 (1) Pentazocine; and

5 (2) Butorphanol (including its optical isomers).

6 (f) Any material, compound, mixture, or preparation which contains
7 any quantity of the following substances, including its salts, isomers,
8 and salts of such isomers, whenever the existence of such salts, isomers,
9 and salts of isomers is possible: Lorcaserin.

10 (g)(1) Unless specifically excepted or unless listed in another
11 schedule, any material, compound, mixture, or preparation which contains
12 any quantity of the following substance, including its salts, optical
13 isomers, and salts of such optical isomers: Ephedrine.

14 (2) The following drug products containing ephedrine, its salts,
15 optical isomers, and salts of such optical isomers, are excepted from
16 subdivision (g)(1) of Schedule IV if they (A) are stored behind a
17 counter, in an area not accessible to customers, or in a locked case so
18 that a customer needs assistance from an employee to access the drug
19 product; (B) are sold by a person, eighteen years of age or older, in the
20 course of his or her employment to a customer eighteen years of age or
21 older with the following restrictions: No customer shall be allowed to
22 purchase, receive, or otherwise acquire more than three and six-tenths
23 grams of ephedrine base during a twenty-four-hour period; no customer
24 shall purchase, receive, or otherwise acquire more than nine grams of
25 ephedrine base during a thirty-day period; and the customer shall display
26 a valid driver's or operator's license, a Nebraska state identification
27 card, a military identification card, an alien registration card, or a
28 passport as proof of identification; (C) are labeled and marketed in a
29 manner consistent with the pertinent OTC Tentative Final or Final
30 Monograph; (D) are manufactured and distributed for legitimate medicinal
31 use in a manner that reduces or eliminates the likelihood of abuse; and

1 (E) are not marketed, advertised, or represented in any manner for the
2 indication of stimulation, mental alertness, euphoria, ecstasy, a buzz or
3 high, heightened sexual performance, or increased muscle mass:

- 4 (i) Primatene Tablets; and
- 5 (ii) Bronkaid Dual Action Caplets.

6 Schedule V

7 (a) Any compound, mixture, or preparation containing any of the
8 following limited quantities of narcotic drugs or salts calculated as the
9 free anhydrous base or alkaloid, which shall include one or more
10 nonnarcotic active medicinal ingredients in sufficient proportion to
11 confer upon the compound, mixture, or preparation valuable medicinal
12 qualities other than those possessed by the narcotic drug alone:

13 (1) Not more than two hundred milligrams of codeine per one hundred
14 milliliters or per one hundred grams;

15 (2) Not more than one hundred milligrams of dihydrocodeine per one
16 hundred milliliters or per one hundred grams;

17 (3) Not more than one hundred milligrams of ethylmorphine per one
18 hundred milliliters or per one hundred grams;

19 (4) Not more than two and five-tenths milligrams of diphenoxylate
20 and not less than twenty-five micrograms of atropine sulfate per dosage
21 unit;

22 (5) Not more than one hundred milligrams of opium per one hundred
23 milliliters or per one hundred grams; and

24 (6) Not more than five-tenths milligram of difenoxin and not less
25 than twenty-five micrograms of atropine sulfate per dosage unit.

26 (b) Unless specifically exempted or excluded or unless listed in
27 another schedule, any material, compound, mixture, or preparation which
28 contains any quantity of the following substances having a stimulant
29 effect on the central nervous system, including its salts, isomers, and
30 salts of isomers: Pyrovalerone.

31 (c) Unless specifically exempted or excluded or unless listed in

1 another schedule, any material, compound, mixture, or preparation which
2 contains any quantity of the following substances having a depressant
3 effect on the central nervous system, including its salts, isomers, and
4 salts of isomers:

5 (1) Ezogabine (N-(2-amino-4-(4-fluorobenzylamino)-phenyl)-carbamic
6 acid ethyl ester);

7 (2) Lacosamide ((R)-2-acetoamido-N-benzyl-3-methoxy-propionamide);

8 (3) Pregabalin ((S)-3-(aminomethyl)-5-methylhexanoic acid); ~~and~~

9 (4) Brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]
10 butanamide) (also referred to as BRV; UCB-34714; Briviact), including its
11 salts; ~~-~~

12 (5) Cenobamate; and

13 (6) Lasmiditan.

14 ~~(d) Cannabidiol in a drug product approved by the federal Food and
15 Drug Administration.~~

16 2. Renumber the remaining sections and correct the repealer
17 accordingly.